Published in Arch Intern Med on August 01, 1989
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet (1984) 4.68
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet (1998) 4.54
Seroepidemiology of HTLV-III antibody in Danish homosexual men: prevalence, transmission, and disease outcome. Br Med J (Clin Res Ed) (1984) 4.39
Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. Development (1995) 4.38
Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA (1985) 4.26
Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. Science (1986) 3.31
Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA (1986) 3.05
Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med (2001) 2.94
Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry (1993) 2.77
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Characterization of motifs which are critical for activity of the cyclic AMP-responsive transcription factor CREB. Mol Cell Biol (1991) 2.27
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg (2012) 2.17
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS (1996) 2.14
Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol (2003) 2.11
Dental HIV transmission? Nature (1993) 2.04
The surgical management of nontraumatic ectopic lenses. J Pediatr Ophthalmol Strabismus (1996) 1.91
Linear IgA disease of adults: association with lymphoproliferative malignancy and possible role of other triggering factors. Br J Dermatol (1990) 1.91
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1996) 1.89
Insulin expression in pancreatic islet cells relies on cooperative interactions between the helix loop helix factor E47 and the homeobox factor STF-1. Mol Endocrinol (1994) 1.89
Comprehensive management of children on a paediatric ward: a family approach. Arch Dis Child (1980) 1.86
The AIDS epidemic. N Engl J Med (1985) 1.82
Possible female-to-female transmission of human immunodeficiency virus. Ann Intern Med (1986) 1.82
Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. Int J Infect Dis (1999) 1.81
An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences. J Virol (1994) 1.81
Overexpression of nef as a marker for restricted HIV-1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology (1994) 1.80
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope. J Infect Dis (1996) 1.61
Effect of T4 count and cofactors on the incidence of AIDS in homosexual men infected with human immunodeficiency virus. JAMA (1987) 1.60
Health education and knowledge assessment of HTLV-III diseases among intravenous drug users. Health Educ Q (1986) 1.58
Transcriptional regulation of the human insulin gene is dependent on the homeodomain protein STF1/IPF1 acting through the CT boxes. Proc Natl Acad Sci U S A (1994) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Occurrence and distribution of serotypes of the Arizona subgroup of Salmonella strains in the United States from 1967 to 1976. J Clin Microbiol (1986) 1.55
Activation of the human immunodeficiency virus by herpes simplex virus type 1. J Virol (1987) 1.55
Design of a safer approach to intravenous drug infusions: failure mode effects analysis. Qual Saf Health Care (2004) 1.55
Effects of one year of supplementation with zinc and other micronutrients on cellular immunity in the elderly. J Am Coll Nutr (1990) 1.52
Development and early natural history of HTLV-III antibodies in persons with hemophilia. JAMA (1985) 1.50
Delayed separation of the umbilical cord, widespread infections, and defective neutrophil mobility. Lancet (1979) 1.50
Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet (1992) 1.49
Absence of detectable antibody in a patient infected with human immunodeficiency virus. Clin Infect Dis (1997) 1.48
Variable role of the long terminal repeat Sp1-binding sites in human immunodeficiency virus replication in T lymphocytes. J Virol (1991) 1.45
HTLV-I/II seroprevalence and HIV/HTLV coinfection among U.S. intravenous drug users. J Acquir Immune Defic Syndr (1991) 1.45
Low occupational risk of human immunodeficiency virus infection among dental professionals. N Engl J Med (1988) 1.43
Hormonal regulation of an islet-specific enhancer in the pancreatic homeobox gene STF-1. Mol Cell Biol (1997) 1.43
Failure of "optimal" four-drug short-course tuberculosis chemotherapy in a compliant patient with human immunodeficiency virus. Am Rev Respir Dis (1987) 1.41
Neurological outcome of methylmalonic acidaemia. Arch Dis Child (1998) 1.40
Catheter ablation of the atrioventricular node using radiofrequency energy. Aust N Z J Med (1994) 1.39
Interpretation of HTLV serology in case reports of new syndromes. Am J Med (1993) 1.38
Duration of human immunodeficiency virus infection before detection of antibody. Lancet (1989) 1.35
Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III. JAMA (1986) 1.33
Breast disease and the general surgeon. II. Effect of audit on the referral of patients with breast problems. Ann R Coll Surg Engl (1993) 1.33
HTLV-III infection among health care workers. Association with needle-stick injuries. JAMA (1985) 1.31
Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins. Clin Exp Immunol (1987) 1.30
Comparison of antigen assay and reverse transcriptase assay for detecting human immunodeficiency virus in culture. J Clin Microbiol (1987) 1.29
Gluten challenge in dermatitis herpetiformis. N Engl J Med (1983) 1.28
Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol (1987) 1.28
Mycoplasma penetrans infection in male homosexuals with AIDS: high seroprevalence and association with Kaposi's sarcoma. Clin Infect Dis (1993) 1.28
Alcoholics Anonymous-Narcotics Anonymous model inpatient treatment of chemically dependent adolescents: a 2-year outcome study. J Stud Alcohol (1991) 1.28
Distinguishing between HTLV-I and HTLV-II by western blot. Lancet (1990) 1.27
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Clinical manifestations of mitochondrial DNA depletion. Neurology (1998) 1.22
The use of peptones as medium additives for the production of a recombinant therapeutic protein in high density perfusion cultures of mammalian cells. Cytotechnology (2000) 1.21
Antibodies reactive with human T cell leukemia viruses in the serum of hemophiliacs receiving factor VIII concentrate. Blood (1985) 1.21
Exposure factors for HIV-1 infection among heterosexual drug abusers in New Jersey treatment programs. AIDS Res Hum Retroviruses (1990) 1.21
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro. Antimicrob Agents Chemother (1995) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
Carcinoembryonic antigen in management of colorectal carcinoma. Br Med J (1974) 1.18
Pancreatic islet expression of the homeobox factor STF-1 relies on an E-box motif that binds USF. J Biol Chem (1996) 1.17
Multiple sclerosis. Pathology of recurrent lesions. Brain (1993) 1.16
Pediatric HIV infection in Elista, Russia: interventional strategies. Am J Public Health (1995) 1.15
The homeodomain protein IPF-1/STF-1 is expressed in a subset of islet cells and promotes rat insulin 1 gene expression dependent on an intact E1 helix-loop-helix factor binding site. Biochem J (1995) 1.15
HLA-DR antibodies and HTLV-III antibody ELISA testing. Lancet (1985) 1.14
Spectral polarization imaging of human prostate cancer tissue using a near-infrared receptor-targeted contrast agent. Technol Cancer Res Treat (2005) 1.14
Tumour markers in breast cancer. Br J Cancer (1979) 1.13
Modelling the long-term cost-effectiveness of endovascular or open repair for abdominal aortic aneurysm. Br J Surg (2008) 1.13
Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle atlantic and central regions of the USA. J Infect Dis (1990) 1.12
Betahistine dihydrochloride treatment facilitates vestibular compensation in the cat. J Vestib Res (1995) 1.12
Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice. Mucosal Immunol (2011) 1.11
Serial pathogenesis study of SIV brain infection. J Med Primatol (1991) 1.10
State laws on tobacco control--United States, 1995. MMWR CDC Surveill Summ (1995) 1.10
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
Mycoplasma genitalium infection and host antibody immune response in patients infected by HIV, patients attending STD clinics and in healthy blood donors. FEMS Immunol Med Microbiol (1997) 1.10
Search for new physics with same-sign isolated dilepton events with jets and missing transverse energy. Phys Rev Lett (2012) 1.09
Presence of human immunodeficiency virus (HIV) type 1, group M, non-B subtypes, Bronx, New York: a sentinel site for monitoring HIV genetic diversity in the United States. J Infect Dis (2000) 1.09
The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther (1998) 1.09
Search for supersymmetry at the LHC in events with jets and missing transverse energy. Phys Rev Lett (2011) 1.08
Immunological response in chronic fatigue syndrome following a graded exercise test to exhaustion. J Clin Immunol (1999) 1.07
Search for stopped Gluinos in pp collisions at square root s=7 TeV. Phys Rev Lett (2011) 1.07
Daniel Carrión and Carrión's disease. Bull Pan Am Health Organ (1991) 1.07
Towards a closed eye model of the pre-ocular tear layer. Prog Retin Eye Res (2000) 1.05
Viral and immunologic examination of human immunodeficiency virus type 1-infected, persistently seronegative persons. J Infect Dis (1999) 1.05
Measurement of the Υ1S, Υ2S, and Υ3S polarizations in pp collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2013) 1.05
HIV-1 subtypes among blood donors from Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.04
Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta. J Immunol (1994) 1.03
An in vivo/in vitro comparison with a leuprolide osmotic implant for the treatment of prostate cancer. J Control Release (2001) 1.02
Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther (2008) 1.02
The evolving epidemiology of human T lymphotropic virus type II. J Infect Dis (1994) 1.02